Catalent (NYSE:CTLT) Announces Earnings Results, Misses Expectations By $0.18 EPS

Catalent (NYSE:CTLT) posted its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18), Briefing.com reports. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.10) EPS.

Catalent Price Performance

NYSE CTLT traded up $1.48 during trading hours on Wednesday, hitting $59.96. The company had a trading volume of 3,400,612 shares, compared to its average volume of 2,045,490. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. The firm has a market capitalization of $10.88 billion, a price-to-earnings ratio of -10.65, a PEG ratio of 2.06 and a beta of 1.16. Catalent has a 52 week low of $32.38 and a 52 week high of $61.20. The firm has a 50 day simple moving average of $60.03 and a 200 day simple moving average of $58.02.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CTLT. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. StockNews.com started coverage on shares of Catalent in a research report on Saturday, October 12th. They set a “hold” rating for the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, July 11th. Robert W. Baird reissued a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Finally, Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Nine investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $59.83.

Insider Transactions at Catalent

In other news, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.31% of the company’s stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.